Trial Profile

Single-center, Randomized, Open-label Study to Investigate the Effect of Single-dose Famotidine and Multiple-dose Efavirenz on the Pharmacokinetics of Daridorexant in Healthy Male Subjects

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 02 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daridorexant (Primary) ; Efavirenz; Famotidine
Indications Insomnia; Sleep apnoea syndrome
Focus Pharmacokinetics
Sponsors Idorsia Pharmaceuticals

Most Recent Events

17 Sep 2021 Results of an analysis assessing plasma PK parameters of daridorexant presented at the 2021 American College of Clinical Pharmacology Annual Meeting
09 Aug 2021 Results assessing Effect of gastric pH and of a moderate CYP3A4 inducer on the pharmacokinetics of daridorexant published in the British Journal of Clinical Pharmacology
02 Sep 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com